The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - McKesson
Stock and Other Ownership Interests - McKesson
Contemporary biomarker testing rates in both early and advanced NSCLC: Results from the MYLUNG pragmatic study.
 
Makenzi Colleen Evangelist
Consulting or Advisory Role - AstraZeneca; Mirati Therapeutics; Regeneron; Takeda
 
James Edward Butrynski
Employment - US Oncology
 
John C. Paschold
No Relationships to Disclose
 
Patrick J. Ward
Employment - Bon Secours Mercy Health (I)
Consulting or Advisory Role - Amgen
 
Alexander I. Spira
Leadership - Next Oncology (Inst)
Stock and Other Ownership Interests - Lilly
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; CytomX Therapeutics; Janssen Oncology; Merck; Novartis; Takeda
Consulting or Advisory Role - Amgen; Array BioPharma (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Black Diamond Therapeutics; Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca; Gritstone Bio; Gritstone Bio; incyte; Janssen Research & Development; Jazz Pharmaceuticals; Lilly; Merck (Inst); Mersana; Mirati Therapeutics; Novartis; Regeneron; Sanofi; Sanofi; Takeda
Research Funding - Abbvie (Inst); ADC Therapeutics (Inst); ADC Therapeutics (Inst); Alkermes (Inst); Amgen (Inst); Arch Therapeutics (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); BluPrint Oncology (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); CytomX Therapeutics (Inst); Daiichi Sankyo (Inst); Gritstone Bio (Inst); Ignyta (Inst); Incyte (Inst); Janssen Oncology (Inst); LAM Therapeutics; LAM Therapeutics (Inst); Loxo (Inst); Loxo (Inst); Macrogenics (Inst); Medikine (Inst); MedImmune (Inst); mersana (Inst); Mirati Therapeutics (Inst); nalo therapeutics (Inst); Newlink Genetics (Inst); Novartis (Inst); Plexxikon (Inst); Regeneron; Revolution Medicines (Inst); Roche (Inst); Rubius Therapeutics (Inst); Synthekine (Inst); Synthekine (Inst); Takeda (Inst); Trovagene (Inst)
 
Kashif Ali
No Relationships to Disclose
 
Janet L. Espirito
No Relationships to Disclose
 
David Hakimian
No Relationships to Disclose
 
Robert M. Jotte
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Roche; Mirati Therapeutics
 
Beth Koselke
Employment - McKesson
Stock and Other Ownership Interests - McKesson
Travel, Accommodations, Expenses - McKesson
 
Timothy Larson
No Relationships to Disclose
 
Michael W. Meshad
No Relationships to Disclose
 
Marcus A. Neubauer
Leadership - McKesson
Travel, Accommodations, Expenses - McKesson
 
Katie Ogden
No Relationships to Disclose
 
Rami Owera
No Relationships to Disclose
 
Donald A. Richards
Consulting or Advisory Role - Grail; Ipsen; Mirati Therapeutics; Seattle Genetics/Astellas; Taiho Pharmaceutical
 
Nicholas J. Robert
Employment - McKesson
Leadership - McKesson
Stock and Other Ownership Interests - McKesson; Moderna Therapeutics; Oncolytics (I)
Honoraria - Bristol-Myers Squibb; Roche
Consulting or Advisory Role - Advi; Boehringer Ingelheim; Bristol-Myers Squibb; New Century Health
 
Jennifer M. Walberg
Employment - McKesson
 
Yunfei Wang
Employment - Ontada/McKesson
 
Robert L. Coleman
Employment - US Oncology
Leadership - Onxeo
Stock and Other Ownership Interests - McKesson
Consulting or Advisory Role - Abbvie; Agenus; Alkermes; Alkermes; AstraZeneca/MedImmune; Clovis Oncology; Eisai; Genentech/Roche; Genmab; GlaxoSmithKline; GOG Foundation; Gradalis; Immunogen; Karyopharm Therapeutics; Merck; Merck; Novocure; OncoMed; OncXerna Therapeutics
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Clovis Oncology (Inst); Immunogen (Inst); Lilly (Inst); Merck (Inst); Mirati Therapeutics (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (I)
Travel, Accommodations, Expenses - Array BioPharma; AstraZeneca/MedImmune; Clovis Oncology; Clovis Oncology; GOG Foundation; Merck; Research to Practice; Roche/Genentech; Sotio; Vaniam Group